SPOTLIGHT: Erbitux fails pancreatic cancer study


ImClone's efforts to expand the use of Erbitux ran into an obstacle today as researchers reported that the drug failed a study on pancreatic cancer survival. Shares of ImClone tumbled more than 11 percent on the news. Report